Heartflow Completes $98M Convertible Notes Financing
Summary
Heartflow, Inc., a Mountain View, CA-based leader in AI technology for coronary artery disease (CAD), received additional investments of approximately $98m through the sale and issuance of convertible notes by its parent company, Heartflow Holding, Inc. This included new investment by Fidelity Management & Research Company and additional investments from existing investors including Janus Henderson Investors, Bain Capital Life Sciences, Hayfin, US Venture Partners (USVP), HealthCor, Capricorn Investment Group and Martis Capital. Certain members of Heartflow management and the Board of Directors also participated in the financing. Proceeds from the convertible notes financing will support research and development efforts to further support Heartflow’s continued advancement of the coronary computed tomography angiography (CCTA)+Heartflow pathway as the definitive standard for the non-invasive diagnosis and management of CAD. Heartflow One is a non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed CCTA pathway.